Background: Anastomotic leakage (AL) is a dreaded complication after oesophagectomy. Endoluminal vacuum-assisted closure therapy (EVAC) has been increasingly used as a first-line treatment for AL. We aimed to identify any potential adverse effects of a neoadjuvant therapy (chemotherapy (CT) or radiochemotherapy (RCT)) on EVAC. Methods: We performed a retrospective cohort study at our tertiary centre between 2013 and 2024. All patients who underwent EVAC for AL after oesophagectomy were included in this study. Parameters such as success rate, length of therapy, number of sponges needed, changes in treatment, and survival were analysed. Results: A total of 29 patients were included, 19 of whom received CT/RCT and 10 of whom received no neoadjuvant treatment (NT). There was no significant difference in patient survival (30-day survival rate CT/RCTn= 1 (5.3%) vs. NTn= 1 (10%),p= 0.632), success rate (CT/RCTn= 15 (78.9%) vs. NTn= 9 (90%),p= 0.454), and length of therapy (CT/RCT vs. NT 24.11 vs. 23.8,p= 0.681), the number of sponges required (CT/RCT vs. NT 6.26 vs. 6.6,p= 0.835), and the need for changing treatment (CT/RCTn= 5 (26.3%) vs. NTn= 1 (10%),p= 0.303). Conclusions: NT did not affect the success rate or length of therapy. Thus, we found no significant influence of CT/RCT on EVAC for AL after oesophagectomy.
背景：吻合口漏是食管切除术后一种令人担忧的并发症。腔内负压封闭引流治疗已越来越多地被用作吻合口漏的一线治疗方法。本研究旨在探讨新辅助治疗（化疗或放化疗）对腔内负压封闭引流治疗可能产生的不良影响。方法：我们在2013年至2024年间于本三级医疗中心开展了一项回顾性队列研究。所有在食管切除术后因吻合口漏接受腔内负压封闭引流治疗的患者均被纳入本研究。分析指标包括治疗成功率、治疗时长、所需海绵数量、治疗方案变更情况及患者生存率。结果：共纳入29例患者，其中19例接受化疗/放化疗，10例未接受新辅助治疗。两组患者在生存率（30天生存率：化疗/放化疗组1例（5.3%）vs. 未治疗组1例（10%），p=0.632）、治疗成功率（化疗/放化疗组15例（78.9%）vs. 未治疗组9例（90%），p=0.454）、治疗时长（化疗/放化疗组vs. 未治疗组：24.11天 vs. 23.8天，p=0.681）、所需海绵数量（化疗/放化疗组vs. 未治疗组：6.26个 vs. 6.6个，p=0.835）以及治疗方案变更需求（化疗/放化疗组5例（26.3%）vs. 未治疗组1例（10%），p=0.303）方面均无显著差异。结论：新辅助治疗未影响治疗成功率或治疗时长。因此，本研究发现化疗/放化疗对食管切除术后吻合口漏的腔内负压封闭引流治疗无显著影响。
肿瘤(癌症)患者之家